Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2466460 | 1.00 | RAD52 (0.48) | RAD52OPRM1HTR2CDRD2DRD3 | |
| SCHEMBL12335908 | 1.00 | RAD52 (0.48) | RAD52OPRM1HTR2CDRD2DRD3 | |
| Bromide SCHEMBL2464749 | 0.98 | RAD52 (0.47) | RAD52OPRM1HTR2CDRD2DRD3 | |
| Bromide SCHEMBL13835750 | 0.98 | RAD52 (0.47) | RAD52OPRM1HTR2CDRD2DRD3 | |
| SCHEMBL23777830 | 0.83 | ADRB1 (0.57) | RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL335553 | 0.83 | ADRB1 (0.57) | RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL30996886 | 0.83 | ADRB1 (0.57) | RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL23777738 | 0.83 | ADRB1 (0.57) | RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL27865382 | 0.82 | OPRM1 (0.46) | OPRM1HTR2CDRD2DRD3SLC6A2 | |
| SCHEMBL23777584 | 0.82 | HTR2C (0.55) | RAD52HTR2CDRD2SLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750738-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750738-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750738-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2773352-B1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RES TRIANGLE INST (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9512105-B2 | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512105-B2 | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2016-04-07 | — | — | US | disclosed |
| US-9273027-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2539706-B1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RES TRIANGLE INST (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150005315-A1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005315-A1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2013086496-A2 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2539706-A1 | ARYLPIPERAZONE OPIOID RECEPTOR ANTAGONISTS | Research Triangle Institute (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011106039-A1 | ARYLPIPERAZONE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106039-A1 | ARYLPIPERAZONE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRD1 | RAD52 3754/4885OPRM1 2/4885HTR2C 85/4885 |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRD1 | RAD52 3611/4885OPRM1 2/4885HTR2C 81/4885 |
| US-20150005315-A1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | OPRK1, OPRM1, OPRD1 | RAD52 3307/4885OPRM1 2/4885HTR2C 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.